Aduro Biotech Inc. (ADRO) Receives Consensus Rating of “Hold” from Brokerages
Shares of Aduro Biotech Inc. (NASDAQ:ADRO) have received a consensus recommendation of “Hold” from the eight research firms that are presently covering the company. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $20.00.
Several analysts have recently issued reports on ADRO shares. Roth Capital restated a “buy” rating and set a $22.00 target price on shares of Aduro Biotech in a research report on Monday, July 11th. Zacks Investment Research lowered shares of Aduro Biotech from a “hold” rating to a “sell” rating in a research report on Monday, July 18th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $30.00 price objective on shares of Aduro Biotech in a research report on Friday, August 5th.
Aduro Biotech (NASDAQ:ADRO) traded down 2.33% during trading on Monday, hitting $11.33. 203,992 shares of the stock traded hands. Aduro Biotech has a 12 month low of $7.26 and a 12 month high of $34.95. The firm has a 50-day moving average price of $13.65 and a 200 day moving average price of $13.10. The firm’s market cap is $733.66 million.
Aduro Biotech (NASDAQ:ADRO) last announced its earnings results on Wednesday, August 3rd. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.21. The firm had revenue of $39 million for the quarter, compared to analysts’ expectations of $25.24 million. Aduro Biotech had a negative net margin of 23.69% and a negative return on equity of 9.23%. Aduro Biotech’s quarterly revenue was up 306.3% compared to the same quarter last year. On average, equities analysts forecast that Aduro Biotech will post ($1.39) EPS for the current fiscal year.
In other Aduro Biotech news, insider Thomas W. Dubensky sold 25,000 shares of the company’s stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $15.18, for a total value of $379,500.00. Following the transaction, the insider now directly owns 12,500 shares in the company, valued at approximately $189,750. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Stephen T. Isaacs sold 27,273 shares of the company’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $12.67, for a total transaction of $345,548.91. Following the completion of the transaction, the chief executive officer now owns 129,473 shares in the company, valued at $1,640,422.91. The disclosure for this sale can be found here. 6.50% of the stock is currently owned by company insiders.
A number of institutional investors have recently modified their holdings of the company. Acrospire Investment Management LLC increased its position in shares of Aduro Biotech by 27.6% in the second quarter. Acrospire Investment Management LLC now owns 9,700 shares of the company’s stock worth $110,000 after buying an additional 2,100 shares in the last quarter. BlackRock Inc. increased its position in shares of Aduro Biotech by 1,850.5% in the second quarter. BlackRock Inc. now owns 12,600 shares of the company’s stock worth $142,000 after buying an additional 11,954 shares in the last quarter. Parametric Portfolio Associates LLC bought a new position in shares of Aduro Biotech during the second quarter worth approximately $143,000. Creative Planning bought a new position in shares of Aduro Biotech during the second quarter worth approximately $158,000. Finally, Fox Run Management L.L.C. bought a new position in shares of Aduro Biotech during the third quarter worth approximately $174,000. Institutional investors and hedge funds own 29.75% of the company’s stock.
Aduro Biotech Company Profile
Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.